Groundbreaking New Treatments for Early Alzheimer’s Disease will be Presented at Arab Health 2024 by Harley Street Clinician
News
Jan 18th, 2024
- Exciting outcome of new clinical trials offers hope for early-stage diagnosis
In 2023 new-generation medications, in international clinical trials, have demonstrated slowing of the progression of Alzheimer’s Disease and its symptoms. The implications of these historic results for the global Alzheimer’s Disease pandemic will be presented at Arab Health 2024 by Harley Street’s Dr MacSweeney, co-founder and CEO of Re:Cognition Health’s, pioneering Brain & Mind Centers (ABHI Operating theatre, Monday 29th January 14:00).
Re:Cognition Health’s experts have been intimately involved in several groundbreaking clinical trials for these effective new generation treatments, with the first of these entering the market, and many more currently in development, in global clinical trials.
Dr MacSweeney will detail a new perspective and a cautiously optimistic outlook for early-stage Alzheimer’s and how the definition of the disease has changed completely in the light of tremendous recent scientific advances.
This will include the results from Eisai’s “CLARITY” Study for Lecanemab, and Eli Lilly’s TRAILBLAZER-ALZ 2 study for Donanemab. Both studies trialed new monoclonal antibodies against toxic brain amyloid protein, which successfully slowed the progression of Alzheimer’s Disease and its symptoms. The TauRx LUCIDITY study also demonstrated exciting results for a new medication aimed against toxic tau protein in the brain.
“There is every reason to be cautiously optimistic, as these new-generation medications, available in the UK and in international clinical trials, can potentially change an individual’s future,” said Dr MacSweeney speaking ahead of Arab Health 2024.
“As we grow older, Alzheimer’s Disease is the most common cause, by far, of the symptoms listed below and there are no medications on the market in the UK to slow the progression of this disease and its symptoms. If you recognise any of these symptoms in yourself, friends or family, it is important to seek a diagnosis as soon as possible. The most accurate diagnosis, globally, can be achieved through screening for a clinical trial and if confirmed to be due to early symptoms of Alzheimer’s Disease, the same trial could provide the opportunity for an effective treatment.”
Furthermore, new medications are available on the market, now, at Re:Cognition Health’s USA Centers and likely to be at their UK Centers in Harley Street in 2024. This is in addition to multiple newer and potentially even more effective medications still in clinical trial.
Lecanemab – FDA approval for USA granted 2023. Currently, under review by MHRA for UK approval.
Re:Cognition Health’s patients joined a global study cohort of 1,795 volunteers with early-stage Alzheimer's Disease to receive fortnightly infusions of Lecanemab or placebo. Results demonstrated a 27% reduction in the rate of progressive cognitive decline over an 18-month period for those taking Lecanemab compared to those on a placebo. Dr Emer MacSweeney, CEO and Medical Director at Re:Cognition Health, express excitement about these results, emphasising the potential not only as a treatment for early-stage Alzheimer's, but also for the development of multiple new treatments.
Donanemab – Currently under review by FDA for approval.
Re:Cognition Health has managed all patients in the UK who have had an opportunity to gain access to Donanemab via the Trailblazer 2 clinical trial, which enrolled 1,736 participants worldwide. The results demonstrated a 35% reduction in cognitive decline in individuals receiving Donanemab, compared to placebo along with a 40% reduction in functional decline related to daily living activities. The individuals with the mildest cognitive symptoms, at the time of joining the study, demonstrated even more impressive results of more than 60% reduction in functional decline. Dr Emer MacSweeney highlights the significant advancements with Donanemab and its potential to be a groundbreaking treatment.
Individuals experiencing progressive short-term memory loss and difficulties in other aspects of their thinking ability are encouraged to seek expert advice promptly and consider participation in clinical trials.
Alzheimer’s Disease International (ADI), estimates 55 million people worldwide were living with dementia in 2020, a number is expected to triple by 2050, reaching 152 million, due to the ageing global population. The socio-economic impact on healthcare, long-term care and lost productivity, is substantial and without an effective early diagnosis and treatment, the economic, personal and social burden will increase significantly.
No comments posted...
Site Copyright HealthMatters
